Abstract
Objective: We report a case of sequential interaction of phenytoin (PHT) and phenobarbital (PB) with fluorouracil (5-FU). Case report: A male patient aged 60 under treatment with PHT and PB in which serum concentrations of PHT (32.8 μg/ml) and PB (26.7 μg/ml) increased ∼2-fold after the start of postoperative adjuvant therapy with calcium levofolinate (l-LV) and fluorouracil (5-FU). When the drug interactions of this case evaluated using the Drug Interaction Probability Scale, was assessed as "probable". Discussion: In this case, 5-FU increased PHT, which in turn may have increased the PB concentration, suggesting that when fluoropyrimidine antitumor agents are administered to patients receiving PHT in combination with other drugs, some measures should be taken in consideration of secondary effects of antitumor agents on other drugs that may possibly interact with PHT, including frequent monitoring of blood drug concentration.
| Original language | English |
|---|---|
| Pages (from-to) | 862-866 |
| Number of pages | 5 |
| Journal | International Journal of Clinical Pharmacology and Therapeutics |
| Volume | 50 |
| Issue number | 12 |
| DOIs | |
| Publication status | Published - 2012 Dec 1 |
| Externally published | Yes |
Fingerprint
Keywords
- Adverse event
- Drug interaction
- Fluorouracil
- Phenobarbital
- Phenytoin
ASJC Scopus subject areas
- Pharmacology
- Pharmacology (medical)
Cite this
Sequential interaction of phenytoin and phenobarbital with fluorouracil. / Tsuda, Aiko; Miki, Akiko; Togawa, Takeshi; Satoh, Hiroki; Hori, Satoko; Sawada, Yasufumi.
In: International Journal of Clinical Pharmacology and Therapeutics, Vol. 50, No. 12, 01.12.2012, p. 862-866.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Sequential interaction of phenytoin and phenobarbital with fluorouracil
AU - Tsuda, Aiko
AU - Miki, Akiko
AU - Togawa, Takeshi
AU - Satoh, Hiroki
AU - Hori, Satoko
AU - Sawada, Yasufumi
PY - 2012/12/1
Y1 - 2012/12/1
N2 - Objective: We report a case of sequential interaction of phenytoin (PHT) and phenobarbital (PB) with fluorouracil (5-FU). Case report: A male patient aged 60 under treatment with PHT and PB in which serum concentrations of PHT (32.8 μg/ml) and PB (26.7 μg/ml) increased ∼2-fold after the start of postoperative adjuvant therapy with calcium levofolinate (l-LV) and fluorouracil (5-FU). When the drug interactions of this case evaluated using the Drug Interaction Probability Scale, was assessed as "probable". Discussion: In this case, 5-FU increased PHT, which in turn may have increased the PB concentration, suggesting that when fluoropyrimidine antitumor agents are administered to patients receiving PHT in combination with other drugs, some measures should be taken in consideration of secondary effects of antitumor agents on other drugs that may possibly interact with PHT, including frequent monitoring of blood drug concentration.
AB - Objective: We report a case of sequential interaction of phenytoin (PHT) and phenobarbital (PB) with fluorouracil (5-FU). Case report: A male patient aged 60 under treatment with PHT and PB in which serum concentrations of PHT (32.8 μg/ml) and PB (26.7 μg/ml) increased ∼2-fold after the start of postoperative adjuvant therapy with calcium levofolinate (l-LV) and fluorouracil (5-FU). When the drug interactions of this case evaluated using the Drug Interaction Probability Scale, was assessed as "probable". Discussion: In this case, 5-FU increased PHT, which in turn may have increased the PB concentration, suggesting that when fluoropyrimidine antitumor agents are administered to patients receiving PHT in combination with other drugs, some measures should be taken in consideration of secondary effects of antitumor agents on other drugs that may possibly interact with PHT, including frequent monitoring of blood drug concentration.
KW - Adverse event
KW - Drug interaction
KW - Fluorouracil
KW - Phenobarbital
KW - Phenytoin
UR - http://www.scopus.com/inward/record.url?scp=84870210126&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84870210126&partnerID=8YFLogxK
U2 - 10.5414/CP201677
DO - 10.5414/CP201677
M3 - Article
VL - 50
SP - 862
EP - 866
JO - International Journal of Clinical Pharmacology and Therapeutics
JF - International Journal of Clinical Pharmacology and Therapeutics
SN - 0946-1965
IS - 12
ER -